MC2 Therapeutics A/S
MC2 Therapeutics A/S, headquartered in Denmark, is a pioneering biopharmaceutical company focused on developing innovative therapies for dermatological conditions. Founded in 2015, the company has rapidly established itself in the industry, particularly in the field of topical treatments that leverage its proprietary drug delivery technology. With a commitment to enhancing patient outcomes, MC2 Therapeutics offers unique products designed to improve the efficacy and tolerability of existing therapies. Their flagship offerings include advanced formulations that address unmet medical needs in skin health, setting them apart in a competitive market. Recognised for its scientific excellence, MC2 Therapeutics has achieved significant milestones, including successful clinical trials and partnerships that bolster its position as a leader in dermatology. The company continues to expand its operational reach, aiming to transform the landscape of skin treatment through innovation and patient-centric solutions.
DitchCarbon Score
How does MC2 Therapeutics A/S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MC2 Therapeutics A/S's score of 18 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
MC2 Therapeutics A/S's reported carbon emissions
MC2 Therapeutics A/S, headquartered in Denmark (DK), currently does not have any publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). Additionally, there are no documented climate commitments or initiatives aimed at reducing greenhouse gas emissions. As the company operates within the pharmaceutical industry, it is essential for them to consider implementing robust climate strategies to align with global sustainability goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
MC2 Therapeutics A/S is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
